BIOMARIN PHARMACEUTICAL INC's ticker is and the CUSIP is 09061GAH4. A total of 50 filers reported holding BIOMARIN PHARMACEUTICAL INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $4,193,465 | +752.1% | 4,221,000 | +786.8% | 0.04% | +775.0% |
| Q3 2021 | $492,135 | -85.3% | 476,000 | -85.2% | 0.00% | -89.2% |
| Q3 2020 | $3,350,000 | +11864.3% | 3,207,000 | +13843.5% | 0.04% | – |
| Q2 2020 | $28,000 | +21.7% | 23,000 | +4.5% | 0.00% | – |
| Q1 2020 | $23,000 | -80.8% | 22,000 | -80.7% | 0.00% | -100.0% |
| Q4 2019 | $120,000 | -71.2% | 114,000 | -71.4% | 0.00% | -66.7% |
| Q2 2019 | $416,000 | -87.0% | 398,000 | -88.3% | 0.00% | -82.4% |
| Q1 2018 | $3,209,000 | -6.4% | 3,400,000 | -0.9% | 0.02% | +6.2% |
| Q4 2017 | $3,427,000 | – | 3,430,000 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SHENKMAN CAPITAL MANAGEMENT INC | 30,138,000 | $29,510,000 | 3.72% |
| PFM Health Sciences, LP | 45,910,000 | $46,002,000 | 1.72% |
| Cheyne Capital Management (UK) LLP | 2,320,000 | $2,330,000 | 1.47% |
| ADVENT CAPITAL MANAGEMENT /DE/ | 41,077,000 | $41,277,000 | 0.66% |
| SSI INVESTMENT MANAGEMENT LLC | 9,071,000 | $9,068,000 | 0.50% |
| PALISADE CAPITAL MANAGEMENT, LP | 14,548,000 | $14,612,000 | 0.34% |
| RWC Asset Management LLP | 7,500,000 | $7,552,000 | 0.21% |
| KBC Group NV | 400,000 | $40,316,000 | 0.15% |
| PROSPECTOR PARTNERS LLC | 1,000,000 | $1,000,000 | 0.12% |
| MACKAY SHIELDS LLC | 11,822,000 | $11,816,000 | 0.10% |